Flagship-Backed Biotech Uses Naturally-Occurring Molecules to Treat Chronic Disease

Flagship Pioneering has committed $50 million to Montai Health, a biotech that aims to develop therapies for chronic diseases using molecules already found in nature, the companies announced Tuesday. The funding will advance Montai's Conecta platform, which it will use to map what it calls the "world's first Anthromolecule Bioactivity Atlas." The technology searches over 100,000 molecules to find those that can help treat chronic diseases. Discover more…